Targeting of human interferon antagonists
US-9732135-B2 · Aug 15, 2017 · US
Targeting of human interferon antagonists
US10072059B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10072059-B2 |
| Application number | US-201715642989-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 6, 2017 |
| Priority date | Jul 19, 2013 |
| Publication date | Sep 11, 2018 |
| Grant date | Sep 11, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating an autoimmune disease comprising providing to a subject in need thereof an effective amount of a composition comprising a fusion protein, the fusion protein comprising an interferon antagonist and an antibody, wherein the interferon antagonist is a human IFNα2 comprising an R120E mutation and wherein the antibody is directed to CD20. 2. The method of claim 1 , wherein the fusion protein further comprises a link…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
- C07K14/56Primary
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10072059B2 cover?
- The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in tre…
- Who is the assignee on this patent?
- Vib Vzw, Univ Gent, Centre Nat Rech Scient, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/56. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).